5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study

Li-Chi Chen; Tina Yi Jin Hsieh; Maryanne M Senna

doi:10.1016/j.jaad.2024.10.023

5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study

J Am Acad Dermatol. 2024 Oct 21:S0190-9622(24)03030-5. doi: 10.1016/j.jaad.2024.10.023. Online ahead of print.

Authors

Li-Chi Chen¹, Tina Yi Jin Hsieh², Maryanne M Senna³

Affiliations

¹ Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA.
² Department of Obstetrics & Gynecology, Beth Israel Deaconess Medical Center, Boston, MA.
³ Department of Dermatology, Lahey Hospital & Medical Center, Burlington, MA; Department of Dermatology, Harvard Medical School, Boston, MA. Electronic address: [email protected].

PMID: 39442887
DOI: 10.1016/j.jaad.2024.10.023

No abstract available

Keywords: 5α-reductase inhibitors; acne; alopecia; breast cancer; dermatology; dutasteride; epidemiology; finasteride; gynecologic cancer; hair loss; hirsutism; safety.